<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196349</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00077510</org_study_id>
    <nct_id>NCT03196349</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism</brief_title>
  <acronym>COVET</acronym>
  <official_title>Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous
      Thromboembolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine if apixaban is superior to warfarin in the reduction of clinically relevant
      bleeding. Determine if rivaroxaban is superior to warfarin in the reduction of clinically
      relevant bleeding. Determine if apixaban is non-inferior to warfarin in the prevention of
      recurrent venous thromboembolism. Determine if rivaroxaban is non-inferior to warfarin in the
      prevention of recurrent venous thromboembolism. An exploratory comparison of apixaban versus
      rivaroxaban for the prevention of clinically relevant bleeding and recurrent Venous
      Thromboembolism (VTEs) as a secondary objective.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment
  </why_stopped>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">May 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Clinically Relevant Bleeding Events</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Primary outcome of Clinically relevant bleeding (composite of major bleeding (MB) and/or clinically relevant non major bleeding (CRNMB))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Recurrent Venous Thromboembolism (VTE)</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Primary efficacy outcome of recurrent VTE</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Subjects Experiencing Major Bleeding</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Major bleeding</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects Experiencing Clinically Relevant Non-major Bleeding</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Clinically relevant non-major bleeding</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects With Premature Termination of Study Medication</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Premature termination of study medication</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects Experiencing All-cause Mortality</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>All cause mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects Experiencing Vascular Events (Myocardial Infarction, Ischemic Stroke)</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>MI, ischemic stroke, peripheral arterial embolism</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 2.5 MG</intervention_name>
    <description>Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 10 MG</intervention_name>
    <description>Will be randomized to receive open label rivaroxaban of 10mg daily</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        3.1 Inclusion Criteria

        To be eligible for this trial, patients must meet all of the following criteria:

          -  Have confirmed acute, symptomatic, first lower extremity proximal DVT and/or PE that
             is NOT associated with a transient risk factor.

          -  Have completed an initial treatment course of oral anticoagulant therapy for 3-12
             months and have a recommendation from their provider to continue anticoagulation
             indefinitely.

          -  Have the capacity to understand and sign an informed consent form.

          -  Be 18 years of age and older.

          -  Under the direct care of a healthcare provider for treatment of VTE for the length of
             time in the study.

        3.2 Exclusion Criteria

        If a patient meets any of the following criteria, he or she may not be enrolled in the
        study:

          -  Creatinine clearance (CrCl) &lt; 30 mL/min as determined by Cockcroft-Gault formula
             documented within 3 months from date of consent

          -  Significant liver disease (Child-Pugh B or C)

          -  Concomitant use of medications that are strong P-glycoprotein or CYP3A4
             inducers/inhibitors

          -  Another indication for chronic therapeutic-dose anticoagulation, such as atrial
             fibrillation (i.e., rivaroxaban, 10 mg daily, or apixaban, 2.5 mg twice daily, would
             not be appropriate therapy)

          -  A clinical indication for a specific anticoagulant regimen (e.g., warfarin with a
             target INR of 2-3 is recommended for patients with 'triple-positive' antiphospholipid
             syndrome).

          -  Life expectancy &lt; 3 months

          -  Currently pregnant or breast feeding

          -  Unable / unwilling to pay for one (or more) of the treatment options

          -  Active Cancer defined as:

        Diagnosed with cancer within the past 6 months; or Recurrent, regionally advanced or
        metastatic disease; Currently receiving treatment or have received any treatment for cancer
        during the 6 months prior to randomization; or A hematologic malignancy not in complete
        remission

        â€¢ Unwilling / unlikely to agree to follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ortel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <results_first_submitted>July 26, 2019</results_first_submitted>
  <results_first_submitted_qc>July 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2019</results_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03196349/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03196349/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03196349/ICF_004.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Warfarin</title>
          <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
        </group>
        <group group_id="P2">
          <title>Apixaban</title>
          <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
        </group>
        <group group_id="P3">
          <title>Rivaroxaban</title>
          <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No data entered</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated early</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>44 subjects were randomized yet only 31 were on study drug by the 1 month telephone follow up. Due to the study being stopped early some of the data was outstanding in the database which is why the numbers do not add up to 44 in all of the categories.</population>
      <group_list>
        <group group_id="B1">
          <title>Warfarin</title>
          <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
        </group>
        <group group_id="B2">
          <title>Apixaban</title>
          <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Rivaroxaban</title>
          <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>In the Apixaban arm 1 subject was never administered study drug and in the rivaroxaban 2 subjects never received study drug. They were excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Clinically Relevant Bleeding Events</title>
        <description>Primary outcome of Clinically relevant bleeding (composite of major bleeding (MB) and/or clinically relevant non major bleeding (CRNMB))</description>
        <time_frame>Randomization to 12 months</time_frame>
        <population>44 subjects were randomized but analysis was only done on participants that had started therapy by the 1 month telephone visit</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban</title>
            <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinically Relevant Bleeding Events</title>
          <description>Primary outcome of Clinically relevant bleeding (composite of major bleeding (MB) and/or clinically relevant non major bleeding (CRNMB))</description>
          <population>44 subjects were randomized but analysis was only done on participants that had started therapy by the 1 month telephone visit</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Recurrent Venous Thromboembolism (VTE)</title>
        <description>Primary efficacy outcome of recurrent VTE</description>
        <time_frame>Randomization to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban</title>
            <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Recurrent Venous Thromboembolism (VTE)</title>
          <description>Primary efficacy outcome of recurrent VTE</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Experiencing Major Bleeding</title>
        <description>Major bleeding</description>
        <time_frame>Randomization to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban</title>
            <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Major Bleeding</title>
          <description>Major bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Experiencing Clinically Relevant Non-major Bleeding</title>
        <description>Clinically relevant non-major bleeding</description>
        <time_frame>Randomization to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban</title>
            <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Clinically Relevant Non-major Bleeding</title>
          <description>Clinically relevant non-major bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With Premature Termination of Study Medication</title>
        <description>Premature termination of study medication</description>
        <time_frame>Randomization to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban</title>
            <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Premature Termination of Study Medication</title>
          <description>Premature termination of study medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Experiencing All-cause Mortality</title>
        <description>All cause mortality</description>
        <time_frame>Randomization to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban</title>
            <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing All-cause Mortality</title>
          <description>All cause mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Experiencing Vascular Events (Myocardial Infarction, Ischemic Stroke)</title>
        <description>MI, ischemic stroke, peripheral arterial embolism</description>
        <time_frame>Randomization to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Rivaroxaban</title>
            <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Vascular Events (Myocardial Infarction, Ischemic Stroke)</title>
          <description>MI, ischemic stroke, peripheral arterial embolism</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Warfarin</title>
          <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
Warfarin: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
        </group>
        <group group_id="E2">
          <title>Apixaban</title>
          <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
Apixaban 2.5 MG: Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
        </group>
        <group group_id="E3">
          <title>Rivaroxaban</title>
          <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
Rivaroxaban 10 MG: Will be randomized to receive open label rivaroxaban of 10mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Ortel</name_or_title>
      <organization>Duke University</organization>
      <phone>919-684-5350 ext 3</phone>
      <email>thomas.ortel@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

